Phenylketonuria Market Size in the 7MM was ~USD 700 Million in 2023, and it is expected to grow by 2034, according to DelveInsight

The Phenylketonuria Market was valued at ~USD 700 Million in 2023 and is projected to grow at a robust CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Phenylketonuria Market Landscape. By analyzing historical data, current Phenylketonuria Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Phenylketonuria Market is increasingly guided by biomarker-driven strategies. Phenylketonuria is a malignant bone tumor that originates from cartilage-producing cells. Phenylketonuria (PKU) is a rare, inherited genetic disorder in which the body cannot properly break down an amino acid called phenylalanine. Normally, phenylalanine is processed by an enzyme called phenylalanine hydroxylase (PAH). In people with PKU, this enzyme doesn’t work properly due to a gene mutation. As a result, phenylalanine builds up in the blood and brain, which can cause serious health problems.

DelveInsight’s report, “Phenylketonuria Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Phenylketonuria Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Phenylketonuria Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Phenylketonuria Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Phenylketonuria Market Forecast

Key Takeaways from Phenylketonuria Market Report

• The majority of PKU cases are diagnosed in infants due to the high rate of newborn screening. The age‐specific data revealed that most patients affected with PKU were ≤14 years, with nearly 60% cases in the 7MM in 2023.
• According to DelveInsight’s estimates, missense mutation cases accounted for 60%, and nonsense mutations for 5% of the total diagnosed prevalent cases of PKU in 2023 in the 7MM.
• In EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of PKU, followed by France. While Spain had the least number of cases in 2023.
• In 2023, classical PKU recorded the highest number of cases with approximately 11,000 cases based on severity-specific cases of PKU in the United States.
• The leading Phenylketonuria Companies such as NGGT, Jnana Therapeutics, BioMarin, and others.
• Promising Phenylketonuria Therapies such as NGGT002, JNT-517, Pegvaliase, and others.

Phenylketonuria Overview

Phenylketonuria is a rare inherited metabolic disorder in which the body is unable to properly break down an amino acid called phenylalanine, which is found in many protein-containing foods. This happens due to a deficiency or absence of the enzyme phenylalanine hydroxylase, leading to a buildup of phenylalanine in the blood and brain. If left untreated, high phenylalanine levels can cause serious neurological complications, including intellectual disability, developmental delays, behavioral problems, and seizures. PKU is usually detected through newborn screening, and with early diagnosis and lifelong dietary management, primarily a low-phenylalanine diet, individuals with PKU can lead healthy, normal lives.

Get a Free sample for the Phenylketonuria Market Report @ Phenylketonuria Therapeutics Market Size

Key Factors in Phenylketonuria Therapeutics Market

• Rising PKU Prevalence: The prevalence of phenylketonuria is rising globally, driven by improved newborn screening and greater awareness of metabolic disorders.
• Increased Screening Adoption: Expansion of newborn screening programs globally has led to earlier and more frequent detection of PKU, increasing the number of diagnosed patients entering care pathways.
• Emergence of Novel PKU Treatments: The anticipated launch of emerging PKU drugs such as NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others are expected to boost the PKU market growth in the coming years.

Phenylketonuria Epidemiology Segmentation in the 7MM

The Phenylketonuria Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Diagnosed Prevalent Cases
• Mutation-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Phenylketonuria Epidemiology trends @ Phenylketonuria Epidemiology Forecast

Recent Development in the Phenylketonuria Treatment Landscape

• In December 2025, PTC Therapeutics, Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved SEPHIENCE (sepiapterin) for treating phenylketonuria (PKU) in both pediatric and adult patients, across all age groups and disease severities.
• In October 2025, the US FDA agreed to review BioMarin Pharmaceutical Inc.’s supplemental biologics license application (sBLA) for pegvaliase-pqp (Palynziq) to expand its indication to adolescents aged 12–17 years with phenylketonuria (PKU).

Phenylketonuria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Phenylketonuria drugs recently launched in the Phenylketonuria market or expected to get launched during the study period. The analysis covers Phenylketonuria Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Phenylketonuria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Phenylketonuria Companies and Therapies

• Otsuka Pharmaceutical Development & Commercialization Inc.: JNT-517 Tablet
• PTC Therapeutics: Sepiapterin
• Synlogic: SYNB1618/SYNB1934
• Sanofi: SAR444836
• BioMarin Pharmaceutical: Kuvan®
• NGGT INC.: NGGT002

To know more about Phenylketonuria Companies working in the treatment market, visit @ Phenylketonuria Clinical Trials and Therapeutic Assessment

Phenylketonuria Market Drivers

• Rising Awareness and Early Diagnosis

Widespread newborn screening programs across developed countries have significantly improved early detection of Phenylketonuria (PKU). Early diagnosis increases the number of treated patients, thereby expanding the addressable market.

• Advancements in Targeted Therapies

Innovative treatments such as enzyme substitution therapies and gene-based approaches are transforming PKU management. Approvals of therapies like sepiapterin and pegvaliase have expanded therapeutic options beyond strict dietary control.

• Expanding Treatment Eligibility

Regulatory approvals extending indications to broader age groups, including adolescents and adults, are driving market growth by increasing the eligible patient population.

• Strong Pipeline Activity

Several companies are actively developing next-generation therapies, including gene therapies and novel small molecules, which are expected to improve long-term disease control and boost market expansion during the forecast period.

• Improved Reimbursement in Developed Markets

Favorable reimbursement frameworks in the US, Europe, and Japan support patient access to high-cost specialty treatments, positively influencing market uptake.

Phenylketonuria Market Barriers

• High Cost of Treatment

Advanced PKU therapies, particularly biologics and enzyme replacement treatments, are expensive. This creates affordability challenges and limits accessibility in low- and middle-income countries.

• Strict Dietary Compliance Challenges

Although dietary therapy remains the standard of care, long-term adherence to low-phenylalanine diets is difficult, affecting treatment outcomes and patient quality of life.

• Limited Patient Population

PKU is a rare disease, which restricts the overall market size despite premium-priced therapies.

• Regulatory and Development Challenges

Gene therapies and innovative biologics require extensive clinical trials and regulatory scrutiny, which can delay approvals and increase development costs.

• Safety and Long-Term Data Concerns

Certain advanced therapies may have safety concerns or limited long-term data, potentially affecting physician confidence and adoption rates.

Scope of the Phenylketonuria Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Phenylketonuria Companies- NGGT, Jnana Therapeutics, BioMarin and others.
• Phenylketonuria Therapies- NGGT002, JNT-517, Pegvaliase, and others.
• Phenylketonuria Therapeutic Assessment: Phenylketonuria current marketed and Phenylketonuria emerging therapies
• Phenylketonuria Market Dynamics: Phenylketonuria market drivers and Phenylketonuria market barriers
• Phenylketonuria Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Phenylketonuria Unmet Needs, KOL’s views, Analyst’s views, Phenylketonuria Market Access and Reimbursement

Discover more about therapies set to grab the major Phenylketonuria Market Share @ Phenylketonuria Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Phenylketonuria Market Report Introduction

3. Phenylketonuria Executive Summary

4. Phenylketonuria Key Events

5. Phenylketonuria Epidemiology and Market Forecast Methodology

6. Phenylketonuria Market Overview at a Glance

7. Phenylketonuria Disease Background and Overview

8. Phenylketonuria Epidemiology and Patient Population

9. Phenylketonuria Patient Journey

10. Phenylketonuria Marketed Drugs

11. Phenylketonuria Emerging Drugs

12. Phenylketonuria: 7MM Analysis

13. Phenylketonuria Unmet Needs

14. Phenylketonuria SWOT Analysis

15. Phenylketonuria KOL Views

16. Phenylketonuria Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.